<?xml version="1.0" encoding="UTF-8"?>
<p id="p0050">Modulation of systemic immune responses may have a potential role in the treatment of patients with COVID-19. Given the importance of the issue and the lack of a vaccine or proven effective therapy, anti-cytokine therapy such as IL-6, TNFÎ± and IL-1 antagonists have been suggested for the alleviation of hyper-inflammation as the main leading cause of severe adult respiratory distress syndrome (ARDS) in patients with COVID-19 (
 <xref rid="bib31" ref-type="bibr">31</xref>,
 <xref rid="bib32" ref-type="bibr">32</xref>).
</p>
